China Greenlights Clinical Trials for Two Hengrui Pharma Drugs, Approves Another Indication for Breast Cancer Drug

MT Newswires Live06-17

China's drug regulator approved clinical trials for Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) SHR-6914 injection and HRS-7525 tablets, according to separate filings with the Shanghai bourse on Wednesday.

The SHR-6914 injection, produced by subsidiary Suzhou Shengdiya Biopharmaceutical, is indicated for tumors related to prostate cancer.

Hengrui's HRS-7525 tablets are indicated for solid tumors.

The regulator also approved another indication for its dalpiciclib isethionate tablets for early-stage breast cancer with high risk of recurrence, and are hormone receptor-positive and human epidermal growth factor receptor 2-negative.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644790190?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 12:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644790190","market":"sh","top_or_hot":-1,"title":"China Greenlights Clinical Trials for Two Hengrui Pharma Drugs, Approves Another Indication for Breast Cancer Drug","media":"MT Newswires Live","content":"<html><body><p> China's drug regulator approved clinical trials for <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> Pharmaceuticals' (SHA:600276, HKG:1276) SHR-6914 injection and HRS-7525 tablets, according to separate filings with the Shanghai bourse on Wednesday.</p><p>The SHR-6914 injection, produced by subsidiary Suzhou Shengdiya Biopharmaceutical, is indicated for tumors related to prostate cancer.</p><p>Hengrui's HRS-7525 tablets are indicated for solid tumors.</p><p>The regulator also approved another indication for its dalpiciclib isethionate tablets for early-stage breast cancer with high risk of recurrence, and are hormone receptor-positive and human epidermal growth factor receptor 2-negative.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Greenlights Clinical Trials for Two Hengrui Pharma Drugs, Approves Another Indication for Breast Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Greenlights Clinical Trials for Two Hengrui Pharma Drugs, Approves Another Indication for Breast Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-17 12:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> China's drug regulator approved clinical trials for <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> Pharmaceuticals' (SHA:600276, HKG:1276) SHR-6914 injection and HRS-7525 tablets, according to separate filings with the Shanghai bourse on Wednesday.</p><p>The SHR-6914 injection, produced by subsidiary Suzhou Shengdiya Biopharmaceutical, is indicated for tumors related to prostate cancer.</p><p>Hengrui's HRS-7525 tablets are indicated for solid tumors.</p><p>The regulator also approved another indication for its dalpiciclib isethionate tablets for early-stage breast cancer with high risk of recurrence, and are hormone receptor-positive and human epidermal growth factor receptor 2-negative.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828714.EUR","symbol_name":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2644790190","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644790190","pubTimestamp":1781671346,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's drug regulator approved clinical trials for Jiangsu Hengrui Pharmaceuticals'  SHR-6914 injection and HRS-7525 tablets, according to separate filings with the Shanghai bourse on Wednesday.The SHR-6914 injection, produced by subsidiary Suzhou Shengdiya Biopharmaceutical, is indicated for tumors related to prostate cancer.Hengrui's HRS-7525 tablets are indicated for solid tumors.The regulator also approved another indication for its dalpiciclib isethionate tablets for early-stage breast cancer with high risk of recurrence, and are hormone receptor-positive and human epidermal growth factor receptor 2-negative.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK0012":"证金概念","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0028":"国家队","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK0183":"MSCI概念","BK1191":"制药","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK0060":"抗癌","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU0359201612.USD":"贝莱德中国基金A2","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","BK0196":"行业龙头","01276":"恒瑞医药","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK0239":"医药制造","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0188":"融资融券"},"translate_title":"中国批准恒瑞医药两种药物的临床试验，批准另一种乳腺癌药物的适应症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9,"01276":0.9},"content_text":"China's drug regulator approved clinical trials for Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) SHR-6914 injection and HRS-7525 tablets, according to separate filings with the Shanghai bourse on Wednesday.The SHR-6914 injection, produced by subsidiary Suzhou Shengdiya Biopharmaceutical, is indicated for tumors related to prostate cancer.Hengrui's HRS-7525 tablets are indicated for solid tumors.The regulator also approved another indication for its dalpiciclib isethionate tablets for early-stage breast cancer with high risk of recurrence, and are hormone receptor-positive and human epidermal growth factor receptor 2-negative.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644790190","isCrawlerRequest":true}